Inorganic nanoparticles for predictive oncology of breast cancer

Nanomedicine

Volumn 4, Issue 1, 2009, Pages 83-103

  Yezhelyev, Maksym ^a   Yacoub, Rami ^a   O'Regan, Ruth ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Biomarkers; Bionanotechnology; Breast cancer; Molecular profiling; MRI; Nanoparticles; Quantum dots; Raman probes; siRNA; Spectroscopy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; GLYCOPROTEIN ANTIBODY; GOLD NANOPARTICLE; INORGANIC NANOPARTICLE; MACROGOL; NANOCAGE; NANOPARTICLE; NANOSHELL; PACLITAXEL; POLYCAPROLACTONE; PROGESTERONE RECEPTOR; QUANTUM DOT; QUANTUM ROD; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; INORGANIC COMPOUND; METAL NANOPARTICLE;

ASPIRATION BIOPSY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONJUGATION; DRUG MEGADOSE; ENDOMETRIUM CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE TARGETING; GENE THERAPY; HUMAN; HYPERTHERMIC THERAPY; INDIVIDUALIZATION; IRON OVERLOAD; MOLECULAR SIZE; NANOANALYSIS; NANODEVICE; NANOPROBE; NANOTECHNOLOGY; NANOTOXICOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; RADIODIAGNOSIS; RAMAN PROBE; RAMAN SPECTROMETRY; REVIEW; SEMICONDUCTOR; SENTINEL LYMPH NODE; TUMOR BIOPSY; ANIMAL; ARTICLE; BREAST TUMOR; CHEMISTRY; FEMALE; METHODOLOGY; NANOMEDICINE;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; INORGANIC CHEMICALS; METAL NANOPARTICLES; NANOMEDICINE; NANOPARTICLES; QUANTUM DOTS;

EID: 60249097905     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/17435889.4.1.83     Document Type: Review

References (119)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics. CA Cancer J. Clin. 57 (1), 43-66 (2007).
2. Elmore JG, Armstrong K, Lehman CD, Fletcher SW: Screening for breast cancer. JAMA293(10), 1245-1256 (2005).
3. Carney PA, Miglioretti DL, Yankaskas BC et al.: Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann. Intern. Med. 138, 168-175 (2003).
4. Lu AH, Salabas EL, Schuth F: Magnetic NPs: synthesis, protection, functionalization, and application. Angew. Chem. Int. Ed. Engl. 46(8),1222-1244 (2007).
5. Artemov D, Mori N, Ravi R, Bhujwalla ZM: Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 63 (11),2723-2727 (2003).
6. Michel SC, Keller TM, Frohlich JM et al.: Preoperative breast cancer staging: MRI of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology225(2),527-536 (2002).
7. Corog C, Robert P, Idee JM, Port M: Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev.58(14),1471-1504 (2006).
8. Van't Veer LJ, Dai H, van de, Vijver et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature415(6871),530-536 (2002).
9. Chen G, Gharib TG, Huang CC et al.: Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell. Proteomics(4),304-313 (2002).
10. Nishizuka S, Charboneau L, Young L et al.: Proteomic profiling of the NCI-60 cancer cell fines using new high-density reverse-phase lysate microarrays. Proc. Natl Acad. Sci. USA 100(24),14229-14234 (2003).
11. Cheg SL, Iddings DM, Scheri RP, Bilchik AJ: Lymphatic mapping and sentinel node analysis: current concepts and applications. CA Cancer J. Clin. 56(5),292-309 (2006).
12. Kim S, Lim YT, Soltesz EG et al.: Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol.22(1),93-97 (2004).
13. Hama Y, Koyama Y, Urano Y, Choyke PL, Kobayashi H: Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity. Breast Cancer Res. Treat.103(1),23-28 (2007).
14. Cuzick J, Forbes JF, Sestak I et al.: International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J. Natl Cancer Inst.99(4),272-282 (2007).
15. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD: Postmenopausal hormone replacement therapy: scientific review. JAMA288(7),872-81 (2002).
16. Suter TM, Cook-Bruns N, Barton C: Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast13(3),173-183 (2004).
17. Sinha R, Kim GJ, Nie S, Shin DM: Nanotechnology in cancer therapeutics: bioconjugated NPs for drug delivery. Mol. Cancer Ther.5(8),1909-1917 (2006).
18. Batist G, Ramakrishman G, Rao CS et al.: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19(5),1444-1454 (2001).
19. O'Brien ME, Wigler N, Inbar M et al.: Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCL (Caelyx™Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15 (3),440-449 (2004).
20. Park JW: Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res.4(3),95-99 (2002).
21. Hofheinz Rd, Gnad-Vost SU, Beyer U et al.: Liposomal encapsulated anticancer drugs. Anticancer Drugs 16(7),691-707 (2005).
22. Lee CC, MacKay JA, Frechet JM, Szoka FC: Designing dendrimers for biological applications, Nat. Biotechnol.23 (12),1517-1526 (2005).
23. Svenson S, Tomalia DA: Dendrimers in biomedical applications: reflections on the field. Adv. Drug Deliv. Rev. 57(15),2106-2129 (2005).
24. Stark DD, Weissleder R, Elizondo G: Superparamagnetic iron oxide: clinical application as a contrast agent for MRI of the liver. Radiology 168(2),297-301 (1988).
25. Thorek DL, Chen AK, Czupryna J, Tsourkas A: Superparamagnetic iron oxide NP probes for molecular imaging. Ann. Biomed. Eng. 34(l),23-38 (2006).
26. Scherer F, Anton M, Schillinger U et al.: Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther. 9(2), 102-109 (2002).
27. Ito A, Shinkai M, Honda H, Kobayashi T: Medical application of functionalized magnetic NPs. J. Biosci. Bioeng. 100(1), 1-11 (2005).
28. Reddy GR, Bhojani MS, McConville P et al.: Vascular targeted NPs for imaging and treatment of brain tumors. Clin. Cancer Res. 12(22),6677-6686 (2006).
29. Chan WC, Nie S: Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science281(5385),2016-2018 (1998).
30. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H: Quantum dot bioconjugates for imaging, labeling and sensing. Nat. Mater.4 (6),435-446 (2005).
31. Gao X, Cui Y, Levenson RM et al.: In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol.22(8),969-976 (2004).
32. Hag M, Gao X, Su JZ, Nie S: Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Nat. Biotechnol.19(7),631-635 (2001).
33. Waggoner A: Fluorescent labels for proteomics and genomics. Curr. Opin. Chem. Biol. 10(1),62-66 (2006).
34. Xiao Y, Barker PE: Semiconductor nanocrystal probes for human metaphase chromosomes. Nucleic Acids Res. 32(3),E28 (2004).
35. Yezhelyev M, Morris C, Gao X et al.: Simultaneous and quantitative detection of multiple biomarkers in human breast cancers using semiconductor multicolor quantum dots breast cancer research and treatment. Breast Cancer Res. Treat. 94,S48 (2005).
36. Al-Hajj A, Yezhelyev M, Gao X et al.: Simultaneous, quantitative detection of multiple biomarkers in human breast cancers using semiconductor multicolor quantum dots. Proc. Am. Assoc. Cancer Res.47,3587 (2006).
37. Hu JT, Li LS, Yang WD, Manna L, Wang LW, Alivisatos AP: Linearly polarized emission from colloidal semiconductor quantum rods. Science292 (5524),2060-2063 (2001).
38. Rothenberg E, Kazes M, Shaviv E, Banin U: Electric field induced switching of the fluorescence of single semiconductor quantum rods. Nano Lett. 5(8),1581-1586 (2005).
39. Choo-Smith LP, Edwards HG, Endtz HP et al.: Medical applications of Raman spectroscopy: from proof of principle to clinical implementation. Biopolymers67 (1),1-9 (2002).
40. Doering E, Nie S: Spectroscopic tags using dye-embedded NPs and surface-enhanced Raman scattering. Anal. Chem. 75 (22),6171-6176 (2003).
41. Nie S, Emory SR: Probing single molecules and single NPs by surface-enhanced Raman scattering. Science275 (5303),1102-1106 (1997).
42. Moore BD, Stevenson L, Watt A et al.: Rapid and ultra-sensitive determination of enzyme activities using surface-enhanced resonance Raman scattering. Nat. Biotechnol.22(9),1133-1138 (2004).
43. Loo C, Lin A, Hirsch L et al.: Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol. Cancer Res. Treat.3(1),33-40 (2004).
44. Su CH, Sheu HS, Lin CY et al.: Nanoshell magnetic resonance imaging contrast agents. J. Am. Chem. Soc.129 (7),2139-2146 (2007).
45. Daniel MC, Astruc D: Gold NPs: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem. Rev.104(1),293-346 (2004).
46. Paciotti GF, Myer L, Weinreich D et al.: Colloidal gold: a novel NP vector for tumor directed drug delivery. Drug Deliv.11 (3),169-183 (2004).
47. El-Sayed IH, Huang X, El-Sayed MA: Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold NPs. Cancer Lett. 239(1),129-135 (2006).
48. Chen J, Saeki F, Wiley BJ et al.: Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett.5(3),473-477 (2005).
49. Cang H, Sun T, Li ZY et al.: Gold nanocages as contrast agents for spectroscopic optical coherence tomography. Opt. Lett.30(22),3048-50 (2005).
50. Bartella L, Smith CS, Dershaw DD, Liberman L: Imaging breast cancer. Radiol. Clin. North Am. 45(1),45-67 (2007).
51. Hlawatsch A, Teifke A, Schmidt M, Thelen M: Preoperative assessment of breast cancer: sonography versus MRI. AJR Am. J. Roentgenol.179(6),1493-1501 (2002).
52. Will O, Purkayastha S, Chan C et al.: Diagnostic precision of NP-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol.7(1),52-60 (2006).
53. Weissleder R, Hahn PF, Stark DD et al.: Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MRI. Radiology169(2),399-403 (1988).
54. Lee JH, Huh YM, Jun YW et al.: Artificially engineered magnetic NPs for ultra-sensitive molecular imaging. Nat. Med. 13(1),95-99 (2007).
55. Huh YM, Jun YW, Song HT et al.: In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J. Am. Chem. Soc.127 (35),12387-12391 (2005).
56. Mulder WJ, Koole R, Brandwijk RJ et al.: Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett.6(1),1-6 (2006).
57. Prinzen L, Miserus RJ, Dirksen A et al.: Optical and magnetic resonance imaging of cell death and platelet activation using annexin a5-functionalized quantum dots. Nano Lett.7(1),93-100 (2007).
58. Bridot JL, Faure AC, Laurent S et al.: Hybrid gadolinium oxide NPs: multimodal contrast agents for in vivo imaging. J. Am. Chem. Soc.129(16),5076-84 (2007).
59. Kobayashi H, Sato N, Kawamoto S et al.: Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer. Bioconjug. Chem.12(1),100-107 (2001).
60. Artemov D, Mori N, Okollie B, Bhujwalla ZM: MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide NPs. Magn. Reson. Med.49(3),403-408 (2003).
61. Choe YS, Lee KH: Targeted in vivo imaging of angiogenesis: present status and perspectives. Curr. Pharm. Des.13(1),17-31 (2007).
62. 3-targeted molecular imaging and therapy in angiogenesis. Nanomedicine1(2),110-114 (2005).
63. 3-integrin-targeted NPs. Circulation 108(18),2270-2274 (2003).
64. Simberg D, Duza T, Park JH et al.: Biomimetic amplification of NP homing to tumors. Proc. Natl. Acad. Sci. USA104 (3),932-6 (2007).
65. Leuschner C, Kumar CS, Hansel W, Soboyejo W, Zhou J, Hormes J. LHRH-conjugated magnetic iron oxide NPs for detection of breast cancer metastases. Breast Cancer Res. Treat. 99(2),163-176 (2006).
66. Zhou J, Leuschner C, Kumar C, Hormes JF, Soboyejo WO: Sub-cellular accumulation of magnetic NPs in breast tumors and metastases. Biomaterials27 (9),2001-2008 (2006).
67. Hagspiel KD, Neidl KF, Eichenberger AC, Weder W, Marincek B: Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MRI at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 196(2),471-478 (1995).
68. Reimer P, Jahnke N, Fiebich M et al.: Hepatic lesion detection and characterization: value of nonenhanced MRI, superparamagnetic iron oxide-enhanced MRI, and spiral CT-ROC analysis. Radiology2l7(1),152-158 (2000).
69. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann. Oncol.16 (10),1569-1583 (2005).
70. Olsen DA, Ostergaard B, Bokmand S, Wamberg PA, Jakobsen EH, Brandslund I. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clin. Chem. Lab. Med.45(2),177-182 (2007).
71. Thomson TA, Hays MM, Spinelli JJ et al.: HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod. Pathol. 14(11), 1079-1086 (2001).
72. Hanash S: Integrated global profiling of cancer. Nat. Rev. Cancer4(8),638-644 (2004).
73. Ghazani AA, Lee JA, Klostranec J et al.: High throughput quantification of protein expression of cancer antigens in tissue microarray using quantum dot nanocrystals. Nano Lett.6(12),2881-2886 (2006).
74. Xing Y, Chaudry Q, Shen C et al.: Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat. Protoc.2(5),1152-1165 (2007).
75. Giepmans BN, Deerinck TJ, Smarr BL et al.: Correlated light and electron microscopic imaging of multiple endogenous proteins using quantum dots. Nat. Methods2(10),743-749 (2005).
76. Del Castillo P, Llorente AR, Stockert JC: Influence of fixation, exciting light and section thickness on the primary fluorescence of samples for microfluorometric analysis. Basic Appl. Histochem.33(3),251-257 (1989).
77. Chan P, Yuen T, Ruf F et al.: Method for multiplex cellular detection of mRNAs using quantum dot fluorescent in situ hybridization. Nucleic Acids Res.33(18),161 (2005).
78. Bentolina LA, Weiss S: Single-step multicolor fluorescence in situ hybridization using semiconductor quantum dot-DNA conjugates. Cell Biochem. Biophys.45 (1),59-70 (2006).
79. Tholouli E, Hoyland JA, Di Vizio D et al.: Imaging of multiple mRNA targets using quantum dot based in situ hybridization and spectral deconvolution in clinical biopsies. Biochem. Biophys. Res. Commun.348(2),628-636 (2006).
80. Matsuno A, Itoh J, Takekoshi S, Nagashima T, Osamura RY: Three-dimensional imaging of the intracellular localization of growth hormone and prolactin and their mRNA using nanocrystal (quantum dot) and confocal laser scanning microscopy techniques. J. Histochem Cytochem.53(7),833-838 (2005).
81. Lauria R, Perrone F, Carlomagno C et al.: The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer76(10),1772-1778 (1995).
82. Morton DL, Wen DR, Wong JH et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg.127(4),392-399 (1992).
83. Silberman AW, McVay C, Cohen JS et al.: Comparative morbidity of axillary lymph node dissection and the sentinel lymph node technique: implications for patients with breast cancer. Ann. Surg.1,1-6 (2004).
84. Giuliano AE, Kirgan DM, Guenther JM, Morton DL: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann. Surg.220(3),391-398 (1994).
85. Bass SS, Cox CE, Ku NN, Berman C, Reintgen DS: The role of sentinel lymph node biopsy in breast cancer. J. Am. Coll. Surg.189(2),183-94 (1999).
86. Leong SP, Donegan E, Heffernon W, Dean S, Katz JA: Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann. Surg. Oncol.7(5),361-366 (2000).
87. Kim S, Lim YT, Soltesz EG et al.: Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol.22(1),93-97 (2004).
88. Soltesz EG, Kim S, Kim SW et al.: Sentinel lymph node mapping of the gastrointestinal tract by using invisible light. Ann. Surg. Oncol.13(3),386-396 (2006).
89. Soltesz EG, Kim S, Laurence RG et al.: Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann. Thorac. Surg.79(1),269-277 (2005).
90. Zhang T, Stilwell JL, Gerion D et al.: Cellular effect of high doses of silica-coated quantum dot profiled with high throughput gene expression analysis and high content cellomics measurements. Nano Lett.6 (4),800-808 (2006).
91. Hama Y, Koyama Y, Urano Y, Choyke PL, Kobayashi H: Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity. Breast Cancer Res. Treat.103(1) 23-28 (2006).
92. Maeda H, Matsumura Y: Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst.6(3),193-210 (1989).
93. Mansour AM, Drevs J, Esser N et al.: A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res.63(14),4062-4066 (2003).
94. Gorelik E, Galili U, Raz A: On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev.20(3-4), 245-277 (2001).
95. Shenoy DB, Amiji MM: Poly(ethylene oxide)-modified poly(ζ,-caprolactone) NPs for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm.293(1-2),261-270 (2005).
96. Memisoglu-Bilensoy E, Vural I, Bochot A, Renoir JM, Duchene D, Hincal AA.: Tamoxifen citrate loaded amphiphilic β-cyclodextrin NPs: in vitro characterization and cytotoxicity. J. Control Release.104 (3),489-496 (2005).
97. Hu FX, Neoh KG, Kang EK: Synthesis and in vitro anticancer evaluation of tamoxifen-loaded magnetite/PLLA composite NPs. Biomaterials27,5725-5733 (2006).
98. Goble S, Bear HD: Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg. Clin. North Am.83(4),943-71 (2003).
99. Park JW: Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res.4(3),95-99 (2002).
100. Lubbe AS, Bergemann C, Riess H et al.: Clinical experiences with magnetic drug targeting: a Phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res.56(20),4686-4693 (1996).
101. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V: Iron oxide NPs for sustained delivery of anticancer agents. Mol. Phann.2(3),194-205 (2005).
102. Steinhauser I, Spankuch B, Strebhardt K, Langer K: Trastuzumab-modified NPs: optimisation of preparation and uptake in cancer cells. Biomaterials27(28),4975-4983 (2006).
103. Wust P, Hildebrandt B, Sreenivasa G et al.: Hyperthermia in combined treatment of cancer. Lancet Oncol.3(8),487-497 (2002).
104. 111 In-ChL6 NP AMF-induced thermoablative therapy for human breast cancer in mice. J. Nucl. Med.48(3),437-444 (2007).
105. Hirsch LR, Stafford RJ, Bankson J et al.: Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl Acad. Sci. USA100(23),13549-13554 (2003).
106. Lim EH, Danthi N, Bednarski M, Li KC: Integrin αvβ3-targeted molecular imaging and therapy in angiogenesis. Nanomedicine1(2),110-114 (2005).
107. Guccione S, Li KC, Bednarski MD: Vascular-targeted NPs for molecular imaging and therapy. Methods Enzymol.386,219-236 (2004).
108. Traina TA, Rugo HS, Dickler M: Bevacizumab for advanced breast cancer. Hematol. Oncol. Clin. North Am.21(2),303-19 (2007).
109. Mukherjee P, Bhattacharya R, Wang P et al.: Antiangiogenic properties of gold NPs. Clin. Cancer Res.11(9),3530-3534 (2005).
110. Aigner A: Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J. Biomed. Biotechnol.4,71659 (2006).
111. Medarova Z, Pham W, Farrar C, Petkova V, Moore A: In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med13(3),372-327 (2007).
112. Zhang W, Yang H, Kong X et al.: Inhibition of respiratory syncytial virus infection with intranasal siRNA NPs targeting the viral NS1 gene. Nat. Med.11 (1),56-62 (2005).
113. Chen AA, Derfus AM, Khetani SR, Bhatia SN: Quantum dots to monitor RNAi delivery and improve gene silencing. Nucleic Acids Res.33(22),e190 (2005)
114. Tan WB, Jiang S, Zhang Y: Quantum-dot based NPs for targeted silencing of HER2/neu gene via RNA interference. Biomaterials28(8),1565-1571 (2007).
115. Mattheakis LC, Dias JM, Choi YJ et al.: Optical coding of mammalian cells using semiconductor quantum dots. Anal. Biochem.327(2),200-208 (2004).
116. Aldana J, Wang YA, Peng X: Photochemical instability of CdSe nanocrystals coated by hydrophilic thiols. J. Am. Chem. Soc.123(36),8844-8850 (2001).
117. Cho SJ, Maysinger D, Jain M, Roder B, Hackbarth S, Winnik FM: Long-term exposure to CdTe quantum dots causes functional impairments in live cells. Langmuir23(4),1974-1980 (2007).
118. Limaye DA, Shaikh ZA: Cytotoxicity of cadmium and characteristics of its transport in cardiomyocytes. Toxicol. Appl. Pharmacol.154(1),59-66 (1999).
119. Seleverstov O, Zabirnyk O, Zscharnack M et al.: Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation. Nano Lett.6 (12),2826-2832 (2006).